Pyoderma Gangrenosum (PG) is a rare, inflammatory, ulcerative skin disorder belonging to the spectrum of neutrophilic dermatoses. It is characterized by rapidly progressive, painful skin ulcers with undermined, violaceous borders, often triggered by minor trauma (pathergy). Protheragen offers comprehensive preclinical drug and therapy development services for Pyoderma Gangrenosum to expedite your research process.
PG frequently occurs in association with systemic conditions, most commonly inflammatory bowel disease (IBD), rheumatologic disorders, and hematologic malignancies. While the exact incidence is low, estimated at 3-10 cases per million population per year, its debilitating nature, propensity for recurrence, and association with serious underlying diseases underscore the urgent need for effective therapies.
Fig.1 Proposed pathogenesis of Pyoderma Gangrenosum. (Flora, Kozera and Frew, 2022)| Category | Drug Name | Target / Intervention | Mechanistic Validation/Model Data | Development Stage |
| Biologics | Infliximab | TNF-α inhibition | Blocks neutrophil chemotaxis and MMP-9 activation in 3D ulcer models | Clinical use |
| Ustekinumab | IL-12/23p40 inhibition | Suppresses Th17-mediated IL-23/IL-17 axis in refractory PG lesions | Phase III | |
| Baricitinib | JAK1/2 inhibition | Reduces IFN-γ-driven CXCL10 production in PG organoids | Phase III | |
| Emerging Biologics | Imsidolimab | IL-36R antagonism | Abrogates neutrophil extracellular trap (NET) formation in vasculitis models | Phase II |
| Vilobelimab | C5a inhibition | Prevents membrane attack complex deposition in ulcer beds | Phase IIa | |
| Advanced Therapies | Autologous ADSCs | TSG-6-mediated tissue repair | Accelerates re-epithelialization via VEGF/FGF secretion in co-culture models | Preclinical |
Protheragen provides tailored in vitro (2D cell models and 3D skin models) and in vivo animal models to investigate the complex molecular pathologies associated with Pyoderma Gangrenosum. Our models focus on replicating key disease characteristics, allowing for comprehensive preclinical evaluation of therapeutic targets.
In Vivo Pharmacokinetics Services
As a consolidated and capable preclinical research services provider, Protheragen is dedicated to driving therapeutic options for rare skin disorders like Pyoderma Gangrenosum. We offer a full range of services, seamlessly supporting your journey from target identification to drug safety evaluation and DMPK services. Feel free to contact us if you're interested in exploring how we can accelerate your Pyoderma Gangrenosum research.
References
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
